Quidel Corp (QDEL) Tops Q4 EPS by 28c
Get Alerts QDEL Hot Sheet
EPS Growth %: -63.3%
Financial Fact:
Research and development: 8.8M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Quidel Corp (NASDAQ: QDEL) reported Q4 EPS of $0.37, $0.28 better than the analyst estimate of $0.09. Revenue for the quarter came in at $63.6 million versus the consensus estimate of $61.05 million.
"We continue to be pleased with the progress we are making as a company. We rebounded from a slow start to the year and realized a very strong fourth quarter, due in part to market share gains with our Sofia Influenza A+B product, and the largest number of Sofias placed in any quarter since launch," said Douglas Bryant, president and CEO of Quidel Corporation. "Additionally, we received CLIA waiver of Sofia Strep A+ in December, which provides another key opportunity to grow the total number of Sofia installations well beyond our initial goal of 10,000 units running our initial menu of assays."
For earnings history and earnings-related data on Quidel Corp (QDEL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- EQT Corp. (EQT) Tops Q1 EPS by 17c; offers outlook
- Veritex Holdings (VBTX) Misses Q1 EPS by 2c
Create E-mail Alert Related Categories
Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!